Companies2 min read
What plasma economics teach about moats
You cannot buy plasma on a spot market — which is exactly why CSL's industry is the market's best classroom on what a moat actually is.
Investors throw the word "moat" at anything with a logo. Plasma is where the word earns its keep — and CSL, the Australian biotech built on it, is one of the clearest classrooms in the market for what durable advantage actually looks like.
The business, in one paragraph
Plasma therapies start with human plasma, collected from donors — mostly in the United States, where donors are compensated — at licensed collection centres. The plasma is pooled and fractionated: separated into proteins such as immunoglobulin and albumin, then processed into therapies for immune deficiencies, bleeding disorders and more. The raw material is people's time. There is no synthetic shortcut at commercial scale.
Moat one: the collection network
You cannot buy plasma on a spot market the way you buy iron ore. Supply is built centre by centre — find a site, license it, staff it, and persuade donors to come back week after week. A network of hundreds of centres represents decades of accumulated approvals and operating know-how. A competitor with unlimited money still cannot conjure one quickly, because regulators and donor behaviour set the clock, not capital.
Moat two: yield
Fractionation is a scale-and-skill game. Every litre of plasma contains a fixed amount of each protein; the winner is whoever extracts more grams of sellable product per litre and wastes less. Yield gains come from process engineering refined over years, and they compound: better yield means lower cost per gram, which funds more collection, which feeds more fractionation. Scale advantages that feed themselves are the strongest kind there is.
Moat three: the regulator
Every step — centre, pool, plant, product — sits under pharmaceutical-grade regulation. That is a burden for the incumbent and a wall for the entrant. When the price of admission includes years of compliance history, the incumbents' club stays small.
What this teaches beyond plasma
The pattern generalises. Moats worth paying for are usually physical or institutional, not rhetorical: networks that take years to assemble, process knowledge that lives in thousands of small refinements, regulatory standing that cannot be bought. When any company claims an advantage, ask the plasma question: if a rival had ten times the capital, what would still take them a decade? If the honest answer is "nothing", it is not a moat. It is a head start.
None of this tells you what any plasma company is worth today — that is a valuation question, and a separate fight. But knowing what a real moat looks like is how you avoid paying moat prices for head starts.
General information only — not personal financial advice.